Quest PharmaTech Company Description

Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer.

The company’s lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for the potential cancer targets include pancreatic, colon, leukemia, ovarian, and breast cancer.

It is also involved in the development of Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer.

The company is headquartered in Edmonton, Canada.

Quest PharmaTech Inc.

Country	Canada
Industry	Biotechnology
Sector	Healthcare
CEO	Ragupathy Madiyalakan

Contact Details

Address: 97 Street NW Edmonton, Alberta T6E 5R9 Canada
Phone	780 448 1400
Website	questpharmatech.com

Stock Details

Ticker Symbol	QPT
Exchange	TSX Venture Exchange
Fiscal Year	February - January
Reporting Currency	CAD
ISIN Number	CA74836M1068
SIC Code	2834

Key Executives

Name	Position
Dr. Ragupathy Madiyalakan Ph.D.	Chief Executive Officer and Director
Pierre Vermette C.A., CPA	Chief Financial Officer
Roger Andrews	Head of Investor Relations and Corporate Communications
Douglas C. Bachman	Vice President of Corporate Development
Thomas Woo	Vice President of Product Development